SCHEMBL2501477

SCHEMBL2501477

Cc1ccc(-c2nccs2)c(C(=O)O)n1.[LiH]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 4/20 0.44
HCRTR2 O43614 4/20 0.44
ECE1 P42892 1/20 0.43
PDPK1 O15530 1/20 0.38
ADORA2A P29274 1/20 0.35
ADORA2B P29275 1/20 0.35
ADORA1 P30542 1/20 0.35
THRA P10827 1/20 0.35
THRB P10828 1/20 0.35
SPHK2 Q9NRA0 1/20 0.35
SPHK1 Q9NYA1 1/20 0.35
AKR1C3 P42330 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.34
SLC6A9 P48067 1/20 0.34
ALDH1A1 P00352 2/20 0.34
MAT2A P31153 1/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7910536 0.98 HCRTR1 (0.45) HCRTR1HCRTR2ECE1PDPK1ADORA2A
SCHEMBL30775114 0.98 HCRTR1 (0.45) HCRTR1HCRTR2ECE1PDPK1ADORA2A
Lithium Ion SCHEMBL2501474 0.84 HCRTR1 (0.43) HCRTR1HCRTR2ECE1PDPK1ADORA2A
SCHEMBL2496193 0.83 HCRTR1 (0.45) HCRTR1HCRTR2ECE1ADORA2AADORA2B
SCHEMBL609807 0.80 GAA (0.40) ADORA2AALDH1A1NPC1RAB9A
SCHEMBL7873749 0.78 GAA (0.41) ADORA2AALDH1A1NPC1RAB9A
SCHEMBL607037 0.75 HCRTR2 (0.49) HCRTR1HCRTR2ALDH1A1NPSR1
SCHEMBL29228617 0.75 KDM4E (0.49) ECE1PDPK1PTGDR2ALDH1A1NPSR1
SCHEMBL30417625 0.75 KDM4E (0.49) ECE1PDPK1PTGDR2ALDH1A1NPSR1
SCHEMBL28791477 0.74 HCRTR1 (0.39) HCRTR1HCRTR2ECE1ADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2370426-A1 N-{[(IR,4S,6R-3-(2-PYRIDINYLCARBONYL)-3-AZABICYCLO [4.1.0]HEPT-4-YL]METHYL}-2-HETEROARYLAMINE DERIVATIVES AND USES THEREOF Glaxo Group Limited (GB) 2011-10-05 EP disclosed
WO-2010063663-A1 N-{[(IR,4S,6R-3-(2-PYRIDINYLCARBONYL)-3-AZABICYCLO [4.1.0]HEPT-4-YL] METHYL}-2-HETEROARYLAMINE DERIVATIVES AND USES THEREOF GLAXO GROUP LIMITED (GB) 2010-06-10 WO disclosed
US-20100144760-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144760-A1 NOVEL COMPOUNDS HTR3B, HTR1B, HTR2B HCRTR1 2016/4885HCRTR2 1425/4885ECE1 2726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.